AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Industrial Minerals Ltd

0.195

+0.03521.88%

Volume:383.15K

Turnover:79.67K

Market Cap:15.66M

PE:-7.89

High:0.230

Open:0.200

Low:0.185

Close:0.160

Loading ...

Overview Company News Filings

Imagion Biosystems advances MagSense HER2 imaging agent with FDA application

Guess which ASX 200 share is up 7% after smashing FY24 guidance

Industrial Minerals Insiders Recover Some Losses, Which Stand At AU$56k

Simply Wall St.

Neurizon Files IND Application to Support HEALEY ALS Platform Trial

INOVIQ: Conceptual success killing breast cancer cells with exosomes

The Market Herald

This ASX healthcare stock is up 160% in a month! Here's why it's just entered a trading halt

Neurotech bounces back from FDA rejection with new NTI164 baseline study

The Market Herald

Sino Biopharmaceutical's Fourth-Gen EGFR Inhibitor's IND Application Gets US FDA Nod

MT Newswires Live

Non-Executive Chairman of Industrial Minerals Ashley Pattison Buys 14% More Shares

Simply Wall St.

InhaleRx procures $38.5m in funding from Clendon Biotech to progress inhaled therapies

InhaleRX snags $38.5M in funding from VC biotech funder Clendon

The Market Herald

Radiopharm locks in cancer-fighting drug manufacturer

The West Australian

Radiopharm closes in on cancer-fighting drug approval

The West Australian

Argenica Therapeutics Posts Positive Studies Results Required by US FDA for IND Application, Says Euroz Hartleys

MT Newswires Live

Jacobio Pharmaceuticals Group Cancer Drug's IND Application Gets NDMA's Nod

MT Newswires Live

BUZZ-Australia's Argenica Therapeutics jumps on positive test results for FDA application

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/IND.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IND.AU"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IND.AU\",,,,,undefined,":{"symbol":"IND.AU","market":"AU","secType":"STK","nameCN":"Industrial Minerals Ltd","latestPrice":0.195,"timestamp":1741151520000,"preClose":0.16,"halted":0,"volume":383147,"delay":0,"changeRate":0.21875,"change":0.035,"floatShares":42536073,"shares":80322500,"eps":-0.024706,"lyrEps":-0.024706,"pbRate":5.59,"amount":79674,"amplitude":0.28125,"volumeRatio":1.7141477914320125,"dividePrice":0,"prevYearClose":0.16,"fiveDayClose":0.105,"twentyDayClose":0.11},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IND.AU\",,,,,undefined,":{"symbol":"IND.AU","floatShares":42536073,"roa":"-31.33%","roe":"-58.38%","lyrEps":-0.024706,"volumeRatio":1.7141477914320125,"shares":80322500,"dividePrice":0,"high":0.23,"amplitude":0.28125,"preClose":0.16,"low":0.185,"week52Low":0.09,"pbRate":"5.59","psRate":"18713.13","week52High":0.325,"institutionHeld":0,"latestPrice":0.195,"committee":-0.77066,"eps":-0.024706,"divideRate":0,"volume":383147,"delay":0,"ttmEps":-0.024706,"open":0.2,"prevYearClose":0.16,"prevWeekClose":0.12,"prevMonthClose":0.12,"prevQuarterClose":0.16,"fiveDayClose":0.105,"twentyDayClose":0.11,"sixtyDayClose":0.15},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IND.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IND.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IND.AU\",pageSize:16,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2512142285","title":"Imagion Biosystems advances MagSense HER2 imaging agent with FDA application","url":"https://stock-news.laohu8.com/highlight/detail?id=2512142285","media":"Small Caps","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512142285?lang=en_us&edition=fundamental","pubTime":"2025-02-19 10:21","pubTimestamp":1739931666,"startTime":"0","endTime":"0","summary":"Cancer detection specialist Imagion Biosystems  has taken the next step in progressing its MagSense HER2 imaging agent, lodging an application with the US Food and Drug Administration .The application for initiated manufacturing of MagSense HER2 is an essential requirement for filing an Investigational New Drug  application with the FDA in mid-2025.The company is developing MagSense HER2 to assist with the assessment of axillary nodal disease in patients diagnosed with HER2+ breast cancer.The HER2-positive subtype of breast cancer is an aggressive phenotype with a high rate of recurrence and metastasis, leading to the need for the development of a more sensitive and specific imaging method.Ultrasound is currently the most commonly employed method for assessing HER2+, with pooled diagnostic sensitivity and specificity of 49% to 87% and 55% to 97%, respectively.Imagion executive chair Bob Proulx said precise nodal staging is an essential component in the management of patients with breas","market":"us","thumbnail":"https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2025/02/Imagion-Biosystems-ASX-IBX-Initiates-Manufacturing-MagSense-breast-cancer.jpg","type":0,"news_type":0,"thumbnails":["https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2025/02/Imagion-Biosystems-ASX-IBX-Initiates-Manufacturing-MagSense-breast-cancer.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://smallcaps.com.au/imagion-biosystems-magsense-her2-imaging-agent-fda-application/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"smallcap_stock","symbols":["BK7095","BK7007","IBX.AU","IND.AU"],"gpt_icon":0},{"id":"2503816568","title":"Guess which ASX 200 share is up 7% after smashing FY24 guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=2503816568","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503816568?lang=en_us&edition=fundamental","pubTime":"2025-01-14 07:21","pubTimestamp":1736810476,"startTime":"0","endTime":"0","summary":"The Telix Pharmaceuticals Ltd  share price is roaring higher on Tuesday morning. At the time of writing, the ASX 200 share is up 7% to $25.79. Why is this ASX 200 share jumping?","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/01/14/guess-which-asx-200-share-is-up-7-after-smashing-fy24-guidance/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7067","BK7095","IND.AU","TLX.AU"],"gpt_icon":0},{"id":"2495696568","title":"Industrial Minerals Insiders Recover Some Losses, Which Stand At AU$56k","url":"https://stock-news.laohu8.com/highlight/detail?id=2495696568","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2495696568?lang=en_us&edition=fundamental","pubTime":"2024-12-31 07:37","pubTimestamp":1735601841,"startTime":"0","endTime":"0","summary":"Insiders who purchased AU$383.6k worth of Industrial Minerals Ltd ( ASX:IND ) shares over the past year recouped some...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/2052000-choice2-main-header/1585186553865","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/2052000-choice2-main-header/1585186553865"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/materials/asx-ind/industrial-minerals-shares/news/industrial-minerals-insiders-recover-some-losses-which-stand","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4109","BK7095","MTX","IND.AU"],"gpt_icon":0},{"id":"2492405339","title":"Neurizon Files IND Application to Support HEALEY ALS Platform Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2492405339","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492405339?lang=en_us&edition=fundamental","pubTime":"2024-12-18 10:59","pubTimestamp":1734490740,"startTime":"0","endTime":"0","summary":"IND application submission to the U.S. Food and Drug Administration  is a pivotal step in initiating a Phase 2/3 clinical study for NUZ-001. The IND is a comprehensive dossier of information, including animal and human studies, pharmacokinetic analyses, toxicology studies, and manufacturing information for NUZ-001. The FDA has a period of 30 days to review the IND application. MELBOURNE, Australia, Dec. 18, 2024 /PRNewswire/ -- , a clinical-stage biotech company advancing treatments for neurodegenerative diseases, is pleased to announce the filing of an Investigational New Drug  application to the U.S. Food and Drug Administration  for its lead candidate, NUZ-001. This milestone is a pivotal step in enabling the commencement of a Phase 2/3 clinical trial within the HEALEY ALS Platform Trial framework. The FDA has a period of 30 days to review the IND application.The IND is the mechanism by which the sponsor provides critical information to the FDA to obtain authorization to initiate th","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/5j5dXN8qUYnlhVgNPlMKYg--~B/aD0xMTM7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/04d0d9d409913dfec3923dc98767d531","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/5j5dXN8qUYnlhVgNPlMKYg--~B/aD0xMTM7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/04d0d9d409913dfec3923dc98767d531"],"rights":{"source":"yahoofinance_au","url":"https://finance.yahoo.com/news/neurizon-files-ind-application-support-025900106.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/neurizon-files-ind-application-support-025900106.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["BK7095","BK7055","MGH.AU","NUZ.AU","BK7096","IND.AU"],"gpt_icon":0},{"id":"2491500187","title":"INOVIQ: Conceptual success killing breast cancer cells with exosomes","url":"https://stock-news.laohu8.com/highlight/detail?id=2491500187","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491500187?lang=en_us&edition=fundamental","pubTime":"2024-12-16 07:56","pubTimestamp":1734306960,"startTime":"0","endTime":"0","summary":"INOVIQ Ltd  has reported early-stage in-vitro success using exosomes from natural killer cells to attack breast cancer cells.Natural killer  cells are what they sound like –naturally occurring elements of the human immune system that use enzymes to attack viruses in the body. Exosomes are released by cells in the body and carry proteins and DNA to other cells.So, in short, INOVIQ is trying to stimulate NK cells to produce exosomes to target breast cancer cells in a petri dish – and according to the company, it’s working. So far, that only shows partial evidence in support of a ‘proof of concept.’。That concept sees INOVIQ being able to attach a chimeric antigen receptor  – a lab-created protein – to the exosomes produced by the NK cells.The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/inoviq-conceptual-success-killing-breast-cancer-cells-with-exosomes-2024-12-16/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["BK7095","BK7503","IIQ.AU","BK4230","BK7002","CAR.AU","BK4022","BK7124","IND.AU","CAR"],"gpt_icon":0},{"id":"2489812271","title":"This ASX healthcare stock is up 160% in a month! Here's why it's just entered a trading halt","url":"https://stock-news.laohu8.com/highlight/detail?id=2489812271","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489812271?lang=en_us&edition=fundamental","pubTime":"2024-12-05 07:25","pubTimestamp":1733354745,"startTime":"0","endTime":"0","summary":"ASX healthcare stock Paradigm Biopharmaceuticals Ltd  has been on a strong run in the past month, soaring 160%.But the drug development company has requested a pause in the trading of its shares before the open on Thursday.Before the halt, Paradigm shares finished the session on Wednesday at 58 cents. Let's take a closer look.Paradigm requested its shares be put on ice starting Thursday, saying that it intends to update the market on a capital raising in the coming days.The pause in trading is expected to remain in place until next Monday, December 9, but trading will resume earlier if the ASX healthcare stock provides an update beforehand.Investors have flooded into Paradigm shares in recent weeks, with prices exploding on optimism surrounding its flagship drug candidate, Zilosul.Last week, the company confirmed it had not received feedback from the US Food and Drug Administration  regarding its revised Phase 3 clinical trial protocol for Zilosul.Meanwhile, Paradigm is also awaiting a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/12/05/this-asx-healthcare-stock-is-up-160-in-a-month-heres-why-its-just-entered-a-trading-halt/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["TGA.AU","BK7095","BK4213","PAR.AU","TGA","BK7001","IND.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"2486488407","title":"Neurotech bounces back from FDA rejection with new NTI164 baseline study","url":"https://stock-news.laohu8.com/highlight/detail?id=2486488407","media":"The Market Herald","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486488407?lang=en_us&edition=fundamental","pubTime":"2024-11-25 07:37","pubTimestamp":1732491420,"startTime":"0","endTime":"0","summary":"Neurotech  has bounced back from a recent fast-track status rejection from the FDA, now launching a NTI164 baseline data study.On October 4, Neurotech flagged to the market the US regulator FDA had knocked back its application for orphan drug status, effectively a fast-track proviso.Orphan drug status is awarded to those compounds seeking to treat rare conditions where few if any treatments are already extant. Tax credits and reduced overall fees are benefits of winning the status, as well as marketing exclusivity rights.But the FDA in October failed to consider as rare enough Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections  and Paediatric Acute- Onset Neuropsychiatric Syndrome  respectively – the two drugs NTI164 is intended to treat.“Although we have demonstrated long term safety and efficacy of NTI164 in paediatric patients across three separate neurological disorders, a PK study is a requirement for global health regulators, including the U","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/neurotech-bounces-back-from-fda-rejection-with-new-baseline-study-for-nti164-2024-11-25/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["NTI.AU","IND.AU","BK4218","BK7095","PK","BK4181","BK7007"],"gpt_icon":0},{"id":"2483664348","title":"Sino Biopharmaceutical's Fourth-Gen EGFR Inhibitor's IND Application Gets US FDA Nod","url":"https://stock-news.laohu8.com/highlight/detail?id=2483664348","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483664348?lang=en_us&edition=fundamental","pubTime":"2024-11-15 16:02","pubTimestamp":1731657747,"startTime":"0","endTime":"0","summary":"Sino Biopharmaceutical  said its fourth-generation EGFR inhibitor TQB3002's application for the investigational new drug  was approved by the US FDA with Phase I clinical trials to begin soon.TQB3002 is a fourth-generation oral small-molecule EGFR inhibitor, which is used to treat cancers, including non-small cell lung cancer, according to a Thursday filing with the Hong Kong bourse","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IND.AU","BK1515","GEN","BK4585","BK4588","BK4097","BK1191","01177","BK7095","BK1589","LU2286300806.USD","BK1521"],"gpt_icon":0},{"id":"2477339949","title":"Non-Executive Chairman of Industrial Minerals Ashley Pattison Buys 14% More Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2477339949","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477339949?lang=en_us&edition=fundamental","pubTime":"2024-10-23 05:00","pubTimestamp":1729630814,"startTime":"0","endTime":"0","summary":"Whilst it may not be a huge deal, we thought it was good to see that the Industrial Minerals Ltd  Non-Executive Chairman, Ashley Pattison, recently bought AU$119k worth of stock, for AU$0.17 per share. That purchase might not be huge but it did increase their holding by 14%.Industrial Minerals Insider Transactions Over The Last Year. Over the last year, we can see that the biggest insider sale was by the insider, Peter Gianni, for AU$3.1m worth of shares, at about AU$0.95 per share. While we don't usually like to see insider selling, it's more concerning if the sales take place at a lower price. The good news is that this large sale was at well above current price of AU$0.18. So it is hard to draw any strong conclusion from it. Peter Gianni was the only individual insider to sell over the last year.You can see a visual depiction of insider transactions  over the last 12 months, below. If you click on the chart, you can see all the individual transactions, including the share price, ind","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/8ou9h1aPnDmM7LIetWUw9Q--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/3eb1acfa01a97be66f224c62f2ff60fd","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/8ou9h1aPnDmM7LIetWUw9Q--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/3eb1acfa01a97be66f224c62f2ff60fd"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/non-executive-chairman-industrial-minerals-210014795.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["BK7095","IND.AU","BK4109","MTX"],"gpt_icon":0},{"id":"2476117764","title":"InhaleRx procures $38.5m in funding from Clendon Biotech to progress inhaled therapies","url":"https://stock-news.laohu8.com/highlight/detail?id=2476117764","media":"Small Caps","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2476117764?lang=en_us&edition=fundamental","pubTime":"2024-10-18 11:01","pubTimestamp":1729220471,"startTime":"0","endTime":"0","summary":"Healthcare company InhaleRx  has entered into an agreement with Melbourne-headquartered Clendon Biotech Capital to provide up to $38.5 million in funding to cover costs associated with developing it’s unique inhaled therapies.Clendon’s funding will fully cover the costs – including those from associated non-clinical work and trial drug manufacturing – for the IRX-211 and IRX-616a drug development plans through to the completion of Phase 2 clinical trials.The funding will also enable InhaleRx to address the requirements of the US Food and Drug Administration  relevant to its recent investigational new drug  application for IRX-616a.IRX-211 is being evaluated for the treatment of breakthrough cancer pain in opioid-tolerant patients, while IRX-616a is an innovative drug-device medication designed to offer fast and effective relief for individuals suffering from the debilitating panic disorder  condition.“While this partnership provides vital support for our clinical development program, w","market":"hk","thumbnail":"https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2024/10/InhaleRX-ASX-IRX-Clendon-Biotech-Capital-funding.jpg","type":0,"news_type":0,"thumbnails":["https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2024/10/InhaleRX-ASX-IRX-Clendon-Biotech-Capital-funding.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://smallcaps.com.au/inhalerx-procures-funding-clendon-biotech-progress-inhaled-therapies/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"smallcap_stock","symbols":["BK4023","BK7094","IRX.AU","LU1169589451.USD","BK7007","BK7095","BK4113","CBD","LU1169590202.USD","IND.AU","PD"],"gpt_icon":0},{"id":"2476449346","title":"InhaleRX snags $38.5M in funding from VC biotech funder Clendon","url":"https://stock-news.laohu8.com/highlight/detail?id=2476449346","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2476449346?lang=en_us&edition=fundamental","pubTime":"2024-10-18 08:47","pubTimestamp":1729212420,"startTime":"0","endTime":"0","summary":"InhaleRX  is set to go ahead with clinical trials of the company’s two key flagship drugs after Victorian VC firm Clendon handed IRX nearly $40M in cash.Targeting “pain management and mental health,” the company is developing cannabis-based compounds for direct inhalation without the need to heat up material per usual vaporisers . This, InhaleRX says, will allow it to offer fast-onset pain relief to large addressable markets. It isn’t clear how, exactly, their product will stand out in an environment already relatively saturated with cannabis-based products.InhaleRX says it’s targeting breakthrough cancer pain with its cannabis-compound-containing inhalers – but that’s a condition for which cannabis prescriptions are already very common amongst those patients who desire to use the product in favour of stronger painkillers like oxycontin. That’s true for Australia, and overseas.Join the discussion: See what HotCopper users are saying about InhaleRX and be part of the conversations that ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/inhalerx-snags-38-5m-in-funding-from-vc-biotech-funder-clendon-2024-10-18/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["LU1815336091.USD","BK4124","IND.AU","VC","IRX.AU","BK7007","LU0757428866.USD","BK7095","BK7094"],"gpt_icon":0},{"id":"2476183702","title":"Radiopharm locks in cancer-fighting drug manufacturer","url":"https://stock-news.laohu8.com/highlight/detail?id=2476183702","media":"The West Australian","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2476183702?lang=en_us&edition=fundamental","pubTime":"2024-10-16 06:25","pubTimestamp":1729031101,"startTime":"0","endTime":"0","summary":"Radiopharm Theranostics has joined forces with a renowned global radiopharmaceutical manufacturer to produce its cancer-fighting treatment that targets commonly over-expressed protein in human tumours.","market":"us","thumbnail":"https://images.thewest.com.au/publication/C-16414211/51b7a227075467c42506894d1abcae9087e07f2c.jpg","type":0,"news_type":0,"thumbnails":["https://images.thewest.com.au/publication/C-16414211/51b7a227075467c42506894d1abcae9087e07f2c.jpg"],"rights":{"source":"thewest_stock","url":"https://thewest.com.au/business/bulls-n-bears/radiopharm-locks-in-cancer-fighting-drug-manufacturer-c-16414211","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://thewest.com.au/business/bulls-n-bears/radiopharm-locks-in-cancer-fighting-drug-manufacturer-c-16414211","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"thewest_stock","symbols":["IND.AU","BK7095"],"gpt_icon":0},{"id":"2472821663","title":"Radiopharm closes in on cancer-fighting drug approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2472821663","media":"The West Australian","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2472821663?lang=en_us&edition=fundamental","pubTime":"2024-10-03 07:08","pubTimestamp":1727910486,"startTime":"0","endTime":"0","summary":"Radiopharm Theranostics has moved closer to securing investigational new drug approval for a cancer-fighting radio-antibody after manufacturing the first batch of its “BetaBart” radiotherapeutic agent.","market":"hk","thumbnail":"https://images.thewest.com.au/publication/C-16268246/d3c937ee1d8532628985b77da56b6540b0797dc1.jpg","type":0,"news_type":0,"thumbnails":["https://images.thewest.com.au/publication/C-16268246/d3c937ee1d8532628985b77da56b6540b0797dc1.jpg"],"rights":{"source":"thewest_stock","url":"https://thewest.com.au/business/bulls-n-bears/radiopharm-closes-in-on-cancer-fighting-drug-approval-c-16268246","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://thewest.com.au/business/bulls-n-bears/radiopharm-closes-in-on-cancer-fighting-drug-approval-c-16268246","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"thewest_stock","symbols":["BK7095","IND.AU"],"gpt_icon":0},{"id":"2470792164","title":"Argenica Therapeutics Posts Positive Studies Results Required by US FDA for IND Application, Says Euroz Hartleys","url":"https://stock-news.laohu8.com/highlight/detail?id=2470792164","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2470792164?lang=en_us&edition=fundamental","pubTime":"2024-09-27 07:22","pubTimestamp":1727392965,"startTime":"0","endTime":"0","summary":"Argenica Therapeutics  posted positive results in several studies required by the US Food and Drug Administration for inclusion in the company's investigational new drug  application to be submitted by the end of 2024, according to a Wednesday research note from Euroz Hartleys.The company's in vivo micronucleus rats study confirmed ARG-007 does not impact genetic material, and a high maximum tolerated dose of 17.5 mg/kg was achieved, well above the therapeutic dose used in the current trial, the broker said.AGN's phase 2 clinical trial in ischaemic stroke patients continues without safety issues and sufficient funding to complete the trial.In addition, trial data showed that the drug has a unique mechanism of action and pharmacological benefits compared with competitors, the broker said.Euroz Hartleys has a speculative buy recommendation on Argenica Therapeutics with a AU$1.40 price target.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","LENZ","BK7095","IND.AU","BK7096","AGN.AU"],"gpt_icon":0},{"id":"2470384205","title":"Jacobio Pharmaceuticals Group Cancer Drug's IND Application Gets NDMA's Nod","url":"https://stock-news.laohu8.com/highlight/detail?id=2470384205","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2470384205?lang=en_us&edition=fundamental","pubTime":"2024-09-26 15:52","pubTimestamp":1727337138,"startTime":"0","endTime":"0","summary":"Jacobio Pharmaceuticals Group  said the Center for Drug Evaluation  of the National Medical Products Administration  approved its Investigational New Drug  application of its cancer drug JAB-23E73, according to a Thursday filing with the Hong Kong bourse.The drug's IND application was previously approved by US FDA, and also plans to initiate the Phase I/IIA clinical trial in advanced solid tumor patients in China and the US.The pharmaceutical stocks were up by almost 3% in recent trading.Price : $1.77, Change: $+0.030, Percent Change: +1.72%","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CDE","BK1574","BK7095","BK1161","BK4588","01167","BK4017","CDE.AU","BK4023","BK4526","BK7050","HKD","IND.AU","BK4585"],"gpt_icon":0},{"id":"2470400189","title":"BUZZ-Australia's Argenica Therapeutics jumps on positive test results for FDA application","url":"https://stock-news.laohu8.com/highlight/detail?id=2470400189","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2470400189?lang=en_us&edition=fundamental","pubTime":"2024-09-25 14:08","pubTimestamp":1727244486,"startTime":"0","endTime":"0","summary":"** Shares of Argenica Therapeutics    rise as much as 12% to A$0.745, logs biggest intraday pct gain since Aug. 14   ** Drug developer reports positive results in safety studies required for Investigational New Drug application  by the U.S. FDA for its ARG-007 drug, aimed at treating acute ischemic stroke, a form of brain stroke     ** IND application is a request for authorisation to administer experimental drugs to humans   ** Co says opening an IND will enable it to conduct later stage clinical trials in the U.S.   ** Stock up 36.3% YTD, as at 0551 GMT ","market":null,"thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AGN.AU","BK7095","XJO.AU","BK7096","XKO.AU","IND.AU","XAO.AU"],"gpt_icon":0}],"pageSize":16,"totalPage":2,"pageCount":1,"totalSize":18}]}}